Cystic Neoplasms of Pancreas

Overview & Types - Cystic Conundrums

Pancreatic Cystic Neoplasms (PCNs): Increasingly detected. Key: Differentiate benign vs. malignant/premalignant.

• SCA (Serous Cystadenoma): Benign. Microcystic pattern ("bunch of grapes"). Central scar. Glycogen-rich cells.
• MCN (Mucinous Cystic Neoplasm): Almost exclusively women (body/tail). Ovarian-type stroma. Premalignant.
• IPMN (Intraductal Papillary Mucinous Neoplasm): Main-duct (MD-IPMN) high-risk vs. Branch-duct (BD-IPMN). Premalignant/Malignant.
• SPN (Solid Pseudopapillary Neoplasm): Young females. Solid & cystic areas. Low-grade malignancy.

⭐ MCNs are found almost exclusively in women (typically perimenopausal) and are characterized by ovarian-type stroma; they do NOT communicate with the pancreatic duct system.

Serous Cystadenoma (SCN) - Benign Bubbles

• Benign; common in elderly women (>60 yrs).
• Microcystic ("honeycomb" - most common), oligocystic, solid types.
• "Sunburst" central scar (often calcified) is pathognomonic.
• Cyst fluid: ↓CEA, ↓Amylase; glycogen-rich (PAS+).
• 📌 SCN: Sunburst Central scar, Serous, Safe (benign).
• Management: Observation if asymptomatic; surgery if symptomatic.

⭐ Associated with Von Hippel-Lindau (VHL) syndrome in some cases.

Mucinous Cystic Neoplasm (MCN) - Ominous Ovarian Stroma

• Almost exclusively in women (95%), typically located in pancreatic body/tail.
• Thick-walled, septated cyst; no communication with pancreatic duct.
• Pathognomonic: Ovarian-type stroma on histology.
• 📌 MCN = Mother (female), Malignant potential, Mucinous, Ovarian stroma.
• Considered premalignant or malignant; can progress to invasive adenocarcinoma.
• Cyst fluid: ↑ CEA, ↓ amylase.
• Management: Surgical resection is standard treatment due to malignant risk.

⭐ The presence of ovarian-type stroma is pathognomonic for MCN and confirms the diagnosis.

IPMN - Duct's Dangerous Dilations

• Mucin-producing neoplasms; cystic dilation of pancreatic ducts.
• Types: Main-Duct (MD-IPMN), Branch-Duct (BD-IPMN), Mixed-Type (MT-IPMN).
• High-Risk Stigmata (HRS): Jaundice, enhancing mural nodule ≥5mm, MPD ≥10mm.
• Worrisome Features (WF): Cyst ≥3cm, MPD 5-9mm, mural nodule <5mm.
• Management: HRS → Resection. WF → EUS. BD-IPMN (no HRS/WF) → Surveillance.

⭐ Main-duct (MD-IPMN) or mixed-type IPMN with main duct involvement generally warrants resection due to high malignancy risk.

SPN (Hamoudi/Gruber-Frantz) - Solidly Surprising

📌 SPN = Solid & Papillary, Young women, Nuclear β-catenin.

• AKA: Frantz tumor; Solid pseudopapillary tumor.
• Typically: Young women (mean age 20-30 yrs).
• Gross: Well-circumscribed, encapsulated; solid & cystic areas with hemorrhage/necrosis.
• Micro: Monotonous cells forming solid sheets & pseudopapillae; hyaline globules, foamy histiocytes.
• Molecular: CTNNB1 (β-catenin) gene mutations.
• Prognosis: Low malignant potential; >95% survival after complete resection.

⭐ Nuclear β-catenin staining is a characteristic immunohistochemical finding and diagnostic hallmark for SPN of the pancreas, reflecting CTNNB1 gene mutations.

Diagnosis & Workup - Peeking Pancreatic Pockets

• Imaging (CT/MRI): Defines cyst morphology (size, septa, nodules, MPD link).
• EUS-FNA: Crucial for fluid analysis.
  • Cytology: Detects malignancy.
  • CEA: > 192 ng/mL (Mucinous) vs. < 5 ng/mL (Serous).
  • Glucose: < 50 mg/dL (Mucinous).
  • Amylase: ↑ in pseudocysts, communicating IPMN.
  • Molecular: KRAS/GNAS (IPMN).
• Serum CA 19-9: Low specificity for cysts.

⭐ Cyst fluid CEA > 192 ng/mL strongly suggests a mucinous neoplasm (IPMN or MCN).

High‑Yield Points - ⚡ Biggest Takeaways

• Serous cystadenomas (SCAs): Benign, microcystic, central scar, "grandmother" lesions.
• Mucinous cystic neoplasms (MCNs): Women (body/tail), ovarian stroma, premalignant.
• IPMNs: Involve ducts; main duct type has ↑ malignant risk vs. branch duct.
• Solid pseudopapillary neoplasms (SPNs): Young females, low malignant potential, β-catenin alterations.
• Cyst fluid: ↑ CEA in MCN/IPMN; ↑ amylase if duct communication.
• Sendai/Fukuoka guidelines direct IPMN management.